UA77650C2 - Use of serotonin reuptake inhibitor in combination with deramcyclane - Google Patents

Use of serotonin reuptake inhibitor in combination with deramcyclane Download PDF

Info

Publication number: UA77650C2
Authority: UA; Ukraine
Prior art keywords: serotonin reuptake; reuptake inhibitor; pharmaceutical composition; citalopram; disorder
Prior art date: 1999-12-06

Application number

UA2002065005A

Other languages

English (en)

Ukrainian (uk)

Inventor

Thomas Ivo Franciscus Cramers

Bernard Hendrik Corn Westerink

Original Assignee

Lundbeck & Co As H

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-06

Filing date

2000-06-12

Publication date

2007-01-15

2000-06-12 Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H

2007-01-15 Publication of UA77650C2 publication Critical patent/UA77650C2/uk

Links

239000003772 serotonin uptake inhibitor Substances 0.000 title claims description 51
229940126570 serotonin reuptake inhibitor Drugs 0.000 title claims description 39
150000001875 compounds Chemical class 0.000 claims abstract description 52
239000000203 mixture Substances 0.000 claims abstract description 9
208000019022 Mood disease Diseases 0.000 claims abstract description 8
208000020401 Depressive disease Diseases 0.000 claims abstract description 7
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical group C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims description 61
229960001653 citalopram Drugs 0.000 claims description 60
229960002464 fluoxetine Drugs 0.000 claims description 32
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 31
CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims description 25
229960004038 fluvoxamine Drugs 0.000 claims description 25
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 24
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 24
WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 claims description 24
229960004341 escitalopram Drugs 0.000 claims description 24
229960002296 paroxetine Drugs 0.000 claims description 24
USRHYDPUVLEVMC-FQEVSTJZSA-N dapoxetine Chemical compound C1([C@H](CCOC=2C3=CC=CC=C3C=CC=2)N(C)C)=CC=CC=C1 USRHYDPUVLEVMC-FQEVSTJZSA-N 0.000 claims description 23
229960005217 dapoxetine Drugs 0.000 claims description 23
VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 claims description 23
229960001800 nefazodone Drugs 0.000 claims description 23
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 23
229960002073 sertraline Drugs 0.000 claims description 23
GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 claims description 22
229960004606 clomipramine Drugs 0.000 claims description 22
OJSFTALXCYKKFQ-YLJYHZDGSA-N femoxetine Chemical compound C1=CC(OC)=CC=C1OC[C@@H]1[C@@H](C=2C=CC=CC=2)CCN(C)C1 OJSFTALXCYKKFQ-YLJYHZDGSA-N 0.000 claims description 22
229950003930 femoxetine Drugs 0.000 claims description 22
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims description 22
229960004801 imipramine Drugs 0.000 claims description 22
239000008194 pharmaceutical composition Substances 0.000 claims description 22
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 21
229960004688 venlafaxine Drugs 0.000 claims description 21
239000004480 active ingredient Substances 0.000 claims description 13
239000002552 dosage form Substances 0.000 claims description 12
208000019901 Anxiety disease Diseases 0.000 claims description 9
230000036506 anxiety Effects 0.000 claims description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 7
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 7
239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 7
206010041250 Social phobia Diseases 0.000 claims description 6
208000032841 Bulimia Diseases 0.000 claims description 5
206010006550 Bulimia nervosa Diseases 0.000 claims description 5
208000030814 Eating disease Diseases 0.000 claims description 5
208000019454 Feeding and Eating disease Diseases 0.000 claims description 5
208000011688 Generalised anxiety disease Diseases 0.000 claims description 5
208000008589 Obesity Diseases 0.000 claims description 5
206010036618 Premenstrual syndrome Diseases 0.000 claims description 5
208000031674 Traumatic Acute Stress disease Diseases 0.000 claims description 5
208000026345 acute stress disease Diseases 0.000 claims description 5
208000022531 anorexia Diseases 0.000 claims description 5
208000010877 cognitive disease Diseases 0.000 claims description 5
206010061428 decreased appetite Diseases 0.000 claims description 5
235000014632 disordered eating Nutrition 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 5
208000024732 dysthymic disease Diseases 0.000 claims description 5
208000029364 generalized anxiety disease Diseases 0.000 claims description 5
235000020824 obesity Nutrition 0.000 claims description 5
208000019899 phobic disease Diseases 0.000 claims description 5
208000028173 post-traumatic stress disease Diseases 0.000 claims description 5
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 4
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 4
208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims description 4
208000030990 Impulse-control disease Diseases 0.000 claims description 4
208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 4
208000011117 substance-related disease Diseases 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 2
206010013654 Drug abuse Diseases 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
230000003042 antagnostic effect Effects 0.000 abstract description 8
230000001270 agonistic effect Effects 0.000 abstract description 7
230000002401 inhibitory effect Effects 0.000 abstract description 7
230000000697 serotonin reuptake Effects 0.000 abstract description 5
230000036961 partial effect Effects 0.000 abstract description 4
102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 abstract 2
101710138093 5-hydroxytryptamine receptor 2C Proteins 0.000 abstract 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 140
239000005557 antagonist Substances 0.000 description 32
229960005417 ketanserin Drugs 0.000 description 30
FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 30
230000000694 effects Effects 0.000 description 29
239000004031 partial agonist Substances 0.000 description 29
229940125425 inverse agonist Drugs 0.000 description 24
102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 21
108091005479 5-HT2 receptors Proteins 0.000 description 21
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
238000002474 experimental method Methods 0.000 description 17
241000700159 Rattus Species 0.000 description 16
239000000556 agonist Substances 0.000 description 15
239000000872 buffer Substances 0.000 description 15
-1 inverse agonist Substances 0.000 description 14
229950009626 ritanserin Drugs 0.000 description 13
JUQLTPCYUFPYKE-UHFFFAOYSA-N ritanserin Chemical compound CC=1N=C2SC=CN2C(=O)C=1CCN(CC1)CCC1=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 JUQLTPCYUFPYKE-UHFFFAOYSA-N 0.000 description 13
229940076279 serotonin Drugs 0.000 description 13
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 12
238000000034 method Methods 0.000 description 12
238000007920 subcutaneous administration Methods 0.000 description 12
238000012360 testing method Methods 0.000 description 12
210000004027 cell Anatomy 0.000 description 10
210000001320 hippocampus Anatomy 0.000 description 10
230000001965 increasing effect Effects 0.000 description 10
239000000243 solution Substances 0.000 description 10
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
102000005962 receptors Human genes 0.000 description 9
108020003175 receptors Proteins 0.000 description 9
230000001225 therapeutic effect Effects 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
238000011260 co-administration Methods 0.000 description 8
238000001690 micro-dialysis Methods 0.000 description 8
UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 7
239000007788 liquid Substances 0.000 description 7
229960003955 mianserin Drugs 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
238000004128 high performance liquid chromatography Methods 0.000 description 6
210000002381 plasma Anatomy 0.000 description 6
238000013105 post hoc analysis Methods 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
150000003839 salts Chemical class 0.000 description 6
239000000523 sample Substances 0.000 description 6
208000035475 disorder Diseases 0.000 description 5
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000003814 drug Substances 0.000 description 5
239000003215 serotonin 5-HT2 receptor antagonist Substances 0.000 description 5
239000003826 tablet Substances 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
208000028698 Cognitive impairment Diseases 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
230000009471 action Effects 0.000 description 4
230000001430 anti-depressive effect Effects 0.000 description 4
239000000935 antidepressant agent Substances 0.000 description 4
229940005513 antidepressants Drugs 0.000 description 4
239000002585 base Substances 0.000 description 4
230000008901 benefit Effects 0.000 description 4
238000000605 extraction Methods 0.000 description 4
208000019906 panic disease Diseases 0.000 description 4
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
101150115343 Tnfsf15 gene Proteins 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
239000002775 capsule Substances 0.000 description 3
238000001514 detection method Methods 0.000 description 3
206010013663 drug dependence Diseases 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
238000007912 intraperitoneal administration Methods 0.000 description 3
239000003446 ligand Substances 0.000 description 3
125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 3
239000002469 receptor inverse agonist Substances 0.000 description 3
GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000012453 solvate Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 2
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 2
108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 2
201000001880 Sexual dysfunction Diseases 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
239000003420 antiserotonin agent Substances 0.000 description 2
230000009118 appropriate response Effects 0.000 description 2
229940090047 auto-injector Drugs 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
238000002648 combination therapy Methods 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000006735 deficit Effects 0.000 description 2
239000003479 dental cement Substances 0.000 description 2
229960003914 desipramine Drugs 0.000 description 2
201000010099 disease Diseases 0.000 description 2
229960003638 dopamine Drugs 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
238000001914 filtration Methods 0.000 description 2
229960002897 heparin Drugs 0.000 description 2
229920000669 heparin Polymers 0.000 description 2
229910000041 hydrogen chloride Inorganic materials 0.000 description 2
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
238000001050 pharmacotherapy Methods 0.000 description 2
239000006187 pill Substances 0.000 description 2
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
239000000843 powder Substances 0.000 description 2
210000002442 prefrontal cortex Anatomy 0.000 description 2
229940044551 receptor antagonist Drugs 0.000 description 2
239000002464 receptor antagonist Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
229960000652 sertindole Drugs 0.000 description 2
231100000872 sexual dysfunction Toxicity 0.000 description 2
210000003625 skull Anatomy 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
230000005062 synaptic transmission Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
229960003991 trazodone Drugs 0.000 description 2
PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
238000005406 washing Methods 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
WLNBMPZUVDTASE-HXIISURNSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;sulfuric acid Chemical compound [O-]S([O-])(=O)=O.O=C[C@H]([NH3+])[C@@H](O)[C@H](O)[C@H](O)CO.O=C[C@H]([NH3+])[C@@H](O)[C@H](O)[C@H](O)CO WLNBMPZUVDTASE-HXIISURNSA-N 0.000 description 1
WIQRCHMSJFFONW-HNNXBMFYSA-N (3s)-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound O([C@@H](CCN)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 WIQRCHMSJFFONW-HNNXBMFYSA-N 0.000 description 1
KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 description 1
ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
WIHMBLDNRMIGDW-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3h-2-benzofuran-5-carbonitrile;hydron;bromide Chemical compound [Br-].O1CC2=CC(C#N)=CC=C2C1(CCC[NH+](C)C)C1=CC=C(F)C=C1 WIHMBLDNRMIGDW-UHFFFAOYSA-N 0.000 description 1
STDYWHYUOSSCBO-UHFFFAOYSA-N 2,3-dimethyl-4-phenyl-4,5-dihydro-1,3-benzodiazepine Chemical compound C1C2=CC=CC=C2N=C(C)N(C)C1C1=CC=CC=C1 STDYWHYUOSSCBO-UHFFFAOYSA-N 0.000 description 1
WETRBJOSGIDJHQ-UHFFFAOYSA-N 2-(3,4-dihydronaphthalen-2-ylmethyl)-4,5-dihydro-1h-imidazole Chemical compound C=1C2=CC=CC=C2CCC=1CC1=NCCN1 WETRBJOSGIDJHQ-UHFFFAOYSA-N 0.000 description 1
NOIIUHRQUVNIDD-UHFFFAOYSA-N 3-[[oxo(pyridin-4-yl)methyl]hydrazo]-N-(phenylmethyl)propanamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 description 1
229940127239 5 Hydroxytryptamine receptor antagonist Drugs 0.000 description 1
JICJBGPOMZQUBB-UHFFFAOYSA-N 7-[(3-chloro-6-methyl-5,5-dioxido-6,11-dihydrodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid Chemical compound O=S1(=O)N(C)C2=CC=CC=C2C(NCCCCCCC(O)=O)C2=CC=C(Cl)C=C21 JICJBGPOMZQUBB-UHFFFAOYSA-N 0.000 description 1
SKTFQHRVFFOHTQ-UHFFFAOYSA-N 8-bromo-1,3-dimethyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 SKTFQHRVFFOHTQ-UHFFFAOYSA-N 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
244000144725 Amygdalus communis Species 0.000 description 1
235000011437 Amygdalus communis Nutrition 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
244000223760 Cinnamomum zeylanicum Species 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 description 1
108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 1
102000015554 Dopamine receptor Human genes 0.000 description 1
108050004812 Dopamine receptor Proteins 0.000 description 1
238000001061 Dunnett's test Methods 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
IWVRVEIKCBFZNF-UHFFFAOYSA-N LSM-1636 Chemical compound C1CNC2CCCC3=C2N1C1=CC=C(C)C=C13 IWVRVEIKCBFZNF-UHFFFAOYSA-N 0.000 description 1
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
241000220225 Malus Species 0.000 description 1
235000011430 Malus pumila Nutrition 0.000 description 1
235000015103 Malus silvestris Nutrition 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
RGPDEAGGEXEMMM-UHFFFAOYSA-N Nefopam Chemical compound C12=CC=CC=C2CN(C)CCOC1C1=CC=CC=C1 RGPDEAGGEXEMMM-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 description 1
108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 1
PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical group OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
101710164184 Synaptic vesicular amine transporter Proteins 0.000 description 1
102100034333 Synaptic vesicular amine transporter Human genes 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
QICQDZXGZOVTEF-UHFFFAOYSA-N [3-(3,4-dichlorophenyl)-2,3-dihydro-1h-inden-1-yl]-methylazanium;chloride Chemical compound Cl.C12=CC=CC=C2C(NC)CC1C1=CC=C(Cl)C(Cl)=C1 QICQDZXGZOVTEF-UHFFFAOYSA-N 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000004913 activation Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
235000020224 almond Nutrition 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
150000001412 amines Chemical group 0.000 description 1
229960000836 amitriptyline Drugs 0.000 description 1
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000000164 antipsychotic agent Substances 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
229960002327 chloral hydrate Drugs 0.000 description 1
208000020832 chronic kidney disease Diseases 0.000 description 1
235000017803 cinnamon Nutrition 0.000 description 1
229960000584 citalopram hydrobromide Drugs 0.000 description 1
XXPVSQRPGBUFKM-SAPNQHFASA-N clovoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(Cl)C=C1 XXPVSQRPGBUFKM-SAPNQHFASA-N 0.000 description 1
229950002663 clovoxamine Drugs 0.000 description 1
229960004170 clozapine Drugs 0.000 description 1
QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
238000001816 cooling Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
SLFGIOIONGJGRT-UHFFFAOYSA-N cyamemazine Chemical compound C1=C(C#N)C=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 SLFGIOIONGJGRT-UHFFFAOYSA-N 0.000 description 1
229960004278 cyamemazine Drugs 0.000 description 1
229950005551 dazepinil Drugs 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
229960002866 duloxetine Drugs 0.000 description 1
210000001951 dura mater Anatomy 0.000 description 1
238000000835 electrochemical detection Methods 0.000 description 1
238000002635 electroconvulsive therapy Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000004744 fabric Substances 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
229950000761 fezolamine Drugs 0.000 description 1
NELSQLPTEWCHQW-UHFFFAOYSA-N fezolamine Chemical compound N=1N(CCCN(C)C)C=C(C=2C=CC=CC=2)C=1C1=CC=CC=C1 NELSQLPTEWCHQW-UHFFFAOYSA-N 0.000 description 1
239000000835 fiber Substances 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
238000001917 fluorescence detection Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000012048 forced swim test Methods 0.000 description 1
239000012458 free base Substances 0.000 description 1
210000005153 frontal cortex Anatomy 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
AKRQHOWXVSDJEF-UHFFFAOYSA-N heptane-1-sulfonic acid Chemical compound CCCCCCCS(O)(=O)=O AKRQHOWXVSDJEF-UHFFFAOYSA-N 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
229910000042 hydrogen bromide Inorganic materials 0.000 description 1
208000013403 hyperactivity Diseases 0.000 description 1
ZHFIAFNZGWCLHU-YPMHNXCESA-N ifoxetine Chemical compound CC1=CC=CC(O[C@@H]2[C@@H](CNCC2)O)=C1C ZHFIAFNZGWCLHU-YPMHNXCESA-N 0.000 description 1
229950006314 ifoxetine Drugs 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000009434 installation Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
229960004194 lidocaine Drugs 0.000 description 1
238000000622 liquid--liquid extraction Methods 0.000 description 1
XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
229910052808 lithium carbonate Inorganic materials 0.000 description 1
MJJDYOLPMGIWND-UHFFFAOYSA-N litoxetine Chemical compound C=1C=C2C=CC=CC2=CC=1COC1CCNCC1 MJJDYOLPMGIWND-UHFFFAOYSA-N 0.000 description 1
229950004138 litoxetine Drugs 0.000 description 1
238000002690 local anesthesia Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical group OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
WZHJKEUHNJHDLS-QTGUNEKASA-N metergoline Chemical compound C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4N(C)C=C(C=34)C2)C1)C)NC(=O)OCC1=CC=CC=C1 WZHJKEUHNJHDLS-QTGUNEKASA-N 0.000 description 1
229960004650 metergoline Drugs 0.000 description 1
GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
229960001186 methysergide Drugs 0.000 description 1
229960003793 midazolam Drugs 0.000 description 1
DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000004050 mood stabilizer Substances 0.000 description 1
229940127237 mood stabilizer Drugs 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
230000008450 motivation Effects 0.000 description 1
229950000323 napamezole Drugs 0.000 description 1
229960000751 nefopam Drugs 0.000 description 1
229960003057 nialamide Drugs 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
229960001158 nortriptyline Drugs 0.000 description 1
239000003921 oil Substances 0.000 description 1
229960005017 olanzapine Drugs 0.000 description 1
KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229960002508 pindolol Drugs 0.000 description 1
PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
229950002220 pirlindole Drugs 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920000333 poly(propyleneimine) Polymers 0.000 description 1
229920002239 polyacrylonitrile Polymers 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000009101 premedication Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000002787 reinforcement Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
229960001534 risperidone Drugs 0.000 description 1
RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000013049 sediment Substances 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229950000319 seproxetine Drugs 0.000 description 1
WPGUWABWNUSPMW-UHFFFAOYSA-N serazapine Chemical compound C1N2C3=CC=CC=C3C(C(=O)OC)=C2C2CN(C)CCN2C2=CC=CC=C21 WPGUWABWNUSPMW-UHFFFAOYSA-N 0.000 description 1
229950004619 serazapine Drugs 0.000 description 1
UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
229960004425 sibutramine Drugs 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
208000022925 sleep disturbance Diseases 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000000946 synaptic effect Effects 0.000 description 1
210000003568 synaptosome Anatomy 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
229960005138 tianeptine Drugs 0.000 description 1
BNKIWXODDDABSJ-UHFFFAOYSA-N tiflucarbine Chemical compound N1C2=CC(F)=C3SC=C(C)C3=C2C2=C1CCN(CC)C2 BNKIWXODDDABSJ-UHFFFAOYSA-N 0.000 description 1
229950008817 tiflucarbine Drugs 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
229940035722 triiodothyronine Drugs 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/9413—Dopamine
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Analytical Chemistry (AREA)
Food Science & Technology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Inorganic Chemistry (AREA)
Nutrition Science (AREA)
Diabetes (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Addiction (AREA)

UA2002065005A 1999-12-06 2000-06-12 Use of serotonin reuptake inhibitor in combination with deramcyclane UA77650C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US16924599P	1999-12-06	1999-12-06
PCT/DK2000/000671 WO2001041701A2 (en)	1999-12-06	2000-12-06	The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist

Publications (1)

Publication Number	Publication Date
UA77650C2 true UA77650C2 (en)	2007-01-15

Family

ID=22614803

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2002065005A UA77650C2 (en)	1999-12-06	2000-06-12	Use of serotonin reuptake inhibitor in combination with deramcyclane

Country Status (33)

Country	Link
US (4)	US20020103249A1 (pl)
EP (2)	EP2036564A1 (pl)
JP (1)	JP2003516326A (pl)
KR (1)	KR100832026B1 (pl)
CN (2)	CN101406465A (pl)
AT (1)	ATE314849T1 (pl)
AU (2)	AU1850801A (pl)
BG (1)	BG106895A (pl)
BR (1)	BR0016385A (pl)
CA (1)	CA2393470A1 (pl)
CO (1)	CO5251409A1 (pl)
CY (1)	CY1105014T1 (pl)
CZ (1)	CZ20021961A3 (pl)
DE (1)	DE60025398T2 (pl)
DK (1)	DK1237553T3 (pl)
EA (1)	EA006391B1 (pl)
ES (1)	ES2255519T3 (pl)
HR (1)	HRP20020527A2 (pl)
HU (1)	HUP0203586A3 (pl)
IL (2)	IL149994A0 (pl)
IS (1)	IS2227B (pl)
ME (1)	MEP6208A (pl)
MX (1)	MXPA02005613A (pl)
NO (1)	NO20022657L (pl)
NZ (1)	NZ545907A (pl)
PL (1)	PL356402A1 (pl)
PT (1)	PT1237553E (pl)
SK (1)	SK7962002A3 (pl)
TR (1)	TR200201512T2 (pl)
UA (1)	UA77650C2 (pl)
WO (2)	WO2001041766A1 (pl)
YU (1)	YU41902A (pl)
ZA (1)	ZA200204391B (pl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR021155A1 (es) *	1999-07-08	2002-06-12	Lundbeck & Co As H	Tratamiento de desordenes neuroticos
GB0005477D0 (en)	2000-03-07	2000-04-26	Resolution Chemicals Limited	Process for the preparation of citalopram
US6589996B2 (en)	2000-03-17	2003-07-08	Orion Corporation	Treatment of disorders relating to the serotonergic system
FI20002612A0 (fi) *	2000-11-28	2000-11-28	Orion Yhtymae Oyj	Yhdistelmäterapia serotoniinivälityksen häiriöiden hoitamiseksi
AU2002218338A1 (en) *	2000-11-28	2002-06-11	Orion Corporation	Treatment of psychiatric disorders with trimethyl-bicyclo(2.2.1)heptane derivatives
US6335372B1 (en) *	2000-11-28	2002-01-01	Orion Corporation	Treatment of obsessive compulsive disorder
US6335371B1 (en) *	2000-11-28	2002-01-01	Orion Corporation	Method for inducing cognition enhancement
EA200301195A1 (ru) *	2001-05-01	2004-04-29	Х. Лундбекк А/С	Применение энантиомерно чистого эсциталопрама
GB0118892D0 (en) *	2001-08-02	2001-09-26	Vernalis Res Ltd	Method of treatment
SE0201544D0 (sv) *	2002-05-17	2002-05-17	Biovitrum Ab	Novel compounds and thier use
MXPA05012493A (es) *	2003-05-27	2006-05-25	Forest Laboratories	Combinacion de un antagonista del receptor de nmda y un inhibidor selectivo de reabsorcion de serotonina para el tratamiento de depresion y otros trastornos de estado de animo.
US20050234093A1 (en) *	2003-06-25	2005-10-20	H. Lundbeck A/S	Treatment of depression and other affective disorders
AR047553A1 (es) *	2003-07-04	2006-01-25	Lundbeck & Co As H	La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
EP1500391A1 (en) *	2003-07-24	2005-01-26	Neuro3D	Therapeutic use of bicycloheptane derivatives
DE602004019118D1 (de)	2003-09-17	2009-03-05	Janssen Pharmaceutica Nv	Kondensierte heterocyclische verbindungen als modulatoren des serotoninrezeptors
US7884096B2 (en)	2003-12-02	2011-02-08	Pharmaneuroboost N.V.	Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1713486A4 (en) *	2003-12-02	2009-04-29	Sheldon Leslie James	COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
WO2005053796A1 (en) *	2003-12-02	2005-06-16	B & B Beheer Nv	Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
US7855195B2 (en)	2003-12-02	2010-12-21	Pharmaneuroboost N.V.	Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050203130A1 (en) *	2003-12-02	2005-09-15	Erik Buntinx	Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050241110A1 (en) *	2004-04-09	2005-11-03	Bruce Baker	Ergonomic handles, especially for garden tools
US7598255B2 (en)	2005-08-04	2009-10-06	Janssen Pharmaceutica Nv	Pyrimidine compounds as serotonin receptor modulators
JP2009538117A (ja) *	2006-03-22	2009-11-05	ハー・ルンドベック・アクチエゼルスカベット	うつ病を処置するための化合物を同定する方法
KR101627901B1 (ko)	2006-06-16	2016-06-13	하. 룬트벡 아크티에 셀스카브	인지기능 장애의 치료를 위한, 세로토닌 재흡수, 5-ht3 및 5-ht1a 활성이 조합된 화합물로서의 1-[2-(2,4-디메틸페닐술파닐)-페닐]피페라진
US20080081067A1 (en) *	2006-10-03	2008-04-03	Gupta Manishkumar	Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
HUE036004T2 (hu) *	2007-08-03	2018-06-28	Richter Gedeon Nyrt	Dopamin receptor ligandumokat tartalmazó gyógyszerkészítmények és kezelési eljárások dopamin receptor ligandumok alkalmazásával
JP2011507835A (ja)	2007-12-21	2011-03-10	アンドレイ・アレクサンドロビッチ・イワシェンコ	α−アドレナリン受容体、ドーパミン、ヒスタミン、イミダゾリン及びセロトニン受容体のリガンド並びにその使用
WO2010006231A1 (en) *	2008-07-10	2010-01-14	Ore Pharmaceuticals Inc.	Treating inflammation and related conditions with irindalone
US8569353B2 (en)	2010-07-15	2013-10-29	Dainippon Sumitomo Pharma Co., Ltd.	Pyrazole compound
EP2629615B1 (en)	2010-10-22	2018-10-10	Duke University	Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies
US10039813B2 (en)	2012-02-07	2018-08-07	Massachusetts Institute Of Technology	Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
WO2014046544A1 (en)	2012-09-21	2014-03-27	Aapa B.V.	Substituted 3-heteroaryloxy-3-(hetero)aryl-propylamines as serotonin transporter and serotonin ht2c receptor modulators
US9724396B2 (en)	2013-03-15	2017-08-08	Massachusetts Institute Of Technology	Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
US10317418B2 (en)	2015-02-24	2019-06-11	Massachusetts Institute Of Technology	Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
WO2016205631A1 (en) *	2015-06-17	2016-12-22	Massachusetts Institute Of Technology	Serotonin 2c receptor antagonists to prevent and treat stress-related trauma disorders
CN107556206A (zh) *	2016-06-30	2018-01-09	陕西合成药业股份有限公司	一种新型5‑羟色胺再摄取抑制剂类化合物及其制备方法和在医学上的应用
US11478467B2 (en)	2017-05-04	2022-10-25	Sreenivasarao Vepachedu	Targeted drug rescue with novel compositions, combinations, and methods thereof
CN119470729B (zh) *	2025-01-15	2025-04-29	山东英盛生物技术有限公司	一种高效液相色谱-串联质谱法定量检测微量血液中霉酚酸的方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8814057D0 (en) *	1988-06-14	1988-07-20	Lundbeck & Co As H	New enantiomers & their isolation
US5155218A (en) *	1990-05-08	1992-10-13	Neurogenetic Corporation	Dna encoding human 5-ht1d receptors
NZ254785A (en)	1992-08-20	1995-09-26	Smithkline Beecham Plc	Heterocyclically-condensed indoles and medicaments
WO1994014801A1 (en)	1992-12-29	1994-07-07	Smithkline Beecham Plc	Heterocyclic urea derivatives as 5ht2c and 5ht2b antagonists
AU670675B2 (en) *	1993-02-10	1996-07-25	Yamanouchi Pharmaceutical Co., Ltd.	Morpholine derivative
GB9313913D0 (en)	1993-07-06	1993-08-18	Smithkline Beecham Plc	Novel compounds
CA2134038C (en) *	1994-06-16	1997-06-03	David Taiwai Wong	Potentiation of drug response
CA2194984C (en)	1994-07-26	2002-07-02	John Eugene Macor	4-indole derivatives as serotonin agonists and antagonists
US5597826A (en) *	1994-09-14	1997-01-28	Pfizer Inc.	Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
GB9420999D0 (en)	1994-10-18	1994-12-07	Smithkline Beecham Plc	Novel compounds
EP0714663A3 (en)	1994-11-28	1997-01-15	Lilly Co Eli	Potentiation of drug responses by serotonin 1A receptor antagonists
WO1996023769A2 (en)	1995-02-02	1996-08-08	Smithkline Beecham Plc	Heterocyclic compounds possessing 5ht2c receptor antagonist activity
SE9501567D0 (sv) *	1995-04-27	1995-04-27	Astra Ab	A new combination
GB9511355D0 (en)	1995-06-06	1995-08-02	Fujisawa Pharmaceutical Co	Urea derivatives
GB9514384D0 (en) *	1995-07-13	1995-09-13	American Home Prod	Medical treatment
GB9517559D0 (en)	1995-08-26	1995-10-25	Smithkline Beecham Plc	Novel compounds
FR2744449B1 (fr)	1996-02-02	1998-04-24	Pf Medicament	Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
GB9607219D0 (en)	1996-04-04	1996-06-12	Smithkline Beecham Plc	Novel compounds
PL186541B1 (pl)	1996-04-12	2004-01-30	Janssen Pharmaceutica Nv	Nowy związek, pochodna izoksazolidyny, kompozycjafarmaceutyczna, zastosowanie pochodnej izoksazolidyny i sposób wytwarzania pochodnej izoksazolidyny
EP0813873B1 (en) *	1996-06-19	2002-02-13	Akzo Nobel N.V.	Pharmaceutical composition comprising mirtazapine and one or more selective serotonin reuptake inhibitors
US5958429A (en) *	1996-08-16	1999-09-28	Eli Lilly And Company	Potentiation of serotonin response
SE9703375D0 (sv) *	1997-09-18	1997-09-18	Astra Ab	A new combination
ID26861A (id) *	1998-05-22	2001-02-15	Lilly Co Eli	Terapi gabungan untuk pengobatan depresi refaktori
US6960577B2 (en) *	1998-05-22	2005-11-01	Eli Lilly And Company	Combination therapy for treatment of refractory depression
NZ507981A (en) *	1998-05-29	2003-10-31	Lilly Co Eli	Combination therapy for treatment of bipolar disorders
DE19827750C1 (de) *	1998-06-22	1999-07-29	Centeon Pharma Gmbh	Verfahren zum Abtrennen von HIV aus einer Flüssigkeit
DE19900673A1 (de) *	1999-01-11	2000-07-13	Basf Ag	Verwendung von Bindungspartnern für 5-HT5-Rezeptoren zur Behandlung neurodegenerativer und neuropsychiatrischer Störungen
US20070259952A1 (en) *	2006-05-02	2007-11-08	H. Lundbeck A/S	Uses of escitalopram

2000
- 2000-06-12 UA UA2002065005A patent/UA77650C2/uk unknown
- 2000-12-04 WO PCT/DK2000/000667 patent/WO2001041766A1/en not_active Ceased
- 2000-12-04 AU AU18508/01A patent/AU1850801A/en not_active Abandoned
- 2000-12-05 CO CO00092734A patent/CO5251409A1/es unknown
- 2000-12-06 JP JP2001542871A patent/JP2003516326A/ja not_active Withdrawn
- 2000-12-06 DK DK00981174T patent/DK1237553T3/da active
- 2000-12-06 HR HRP20020527 patent/HRP20020527A2/hr not_active Application Discontinuation
- 2000-12-06 EP EP08021043A patent/EP2036564A1/en not_active Withdrawn
- 2000-12-06 CA CA002393470A patent/CA2393470A1/en not_active Abandoned
- 2000-12-06 DE DE60025398T patent/DE60025398T2/de not_active Expired - Fee Related
- 2000-12-06 SK SK796-2002A patent/SK7962002A3/sk unknown
- 2000-12-06 CZ CZ20021961A patent/CZ20021961A3/cs unknown
- 2000-12-06 EP EP00981174A patent/EP1237553B1/en not_active Expired - Lifetime
- 2000-12-06 BR BR0016385-6A patent/BR0016385A/pt not_active Application Discontinuation
- 2000-12-06 NZ NZ545907A patent/NZ545907A/en unknown
- 2000-12-06 ES ES00981174T patent/ES2255519T3/es not_active Expired - Lifetime
- 2000-12-06 IL IL14999400A patent/IL149994A0/xx active IP Right Grant
- 2000-12-06 CN CNA2008101499473A patent/CN101406465A/zh active Pending
- 2000-12-06 EA EA200200649A patent/EA006391B1/ru not_active IP Right Cessation
- 2000-12-06 CN CN00818827A patent/CN1433313A/zh active Pending
- 2000-12-06 PT PT00981174T patent/PT1237553E/pt unknown
- 2000-12-06 MX MXPA02005613A patent/MXPA02005613A/es not_active Application Discontinuation
- 2000-12-06 TR TR2002/01512T patent/TR200201512T2/xx unknown
- 2000-12-06 US US09/731,411 patent/US20020103249A1/en not_active Abandoned
- 2000-12-06 KR KR1020027007231A patent/KR100832026B1/ko not_active Expired - Fee Related
- 2000-12-06 ME MEP-62/08A patent/MEP6208A/xx unknown
- 2000-12-06 WO PCT/DK2000/000671 patent/WO2001041701A2/en not_active Ceased
- 2000-12-06 PL PL00356402A patent/PL356402A1/pl not_active Application Discontinuation
- 2000-12-06 YU YU41902A patent/YU41902A/sh unknown
- 2000-12-06 AT AT00981174T patent/ATE314849T1/de not_active IP Right Cessation
- 2000-12-06 AU AU18511/01A patent/AU1851101A/en not_active Abandoned
- 2000-12-06 HU HU0203586A patent/HUP0203586A3/hu unknown
2002
- 2002-05-31 IS IS6404A patent/IS2227B/is unknown
- 2002-05-31 ZA ZA200204391A patent/ZA200204391B/xx unknown
- 2002-06-03 IL IL149994A patent/IL149994A/en not_active IP Right Cessation
- 2002-06-05 NO NO20022657A patent/NO20022657L/no not_active Application Discontinuation
- 2002-06-06 US US10/165,196 patent/US20030032636A1/en not_active Abandoned
- 2002-07-02 BG BG106895A patent/BG106895A/bg unknown
2006
- 2006-03-28 CY CY20061100431T patent/CY1105014T1/el unknown
- 2006-10-05 US US11/539,100 patent/US20070105843A1/en not_active Abandoned
2009
- 2009-03-18 US US12/406,226 patent/US20090176808A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HUP0203586A2 (hu)	2003-03-28
JP2003516326A (ja)	2003-05-13
CA2393470A1 (en)	2001-06-14
CZ20021961A3 (cs)	2002-11-13
IS6404A (is)	2002-05-31
DE60025398T2 (de)	2006-08-03
IS2227B (is)	2007-04-15
US20020103249A1 (en)	2002-08-01
WO2001041766A1 (en)	2001-06-14
MEP6208A (en)	2010-02-10
US20030032636A1 (en)	2003-02-13
NO20022657L (no)	2002-07-26
PL356402A1 (pl)	2004-06-28
US20070105843A1 (en)	2007-05-10
AU1850801A (en)	2001-06-18
IL149994A0 (en)	2002-12-01
BG106895A (bg)	2003-04-30
NO20022657D0 (no)	2002-06-05
PT1237553E (pt)	2006-05-31
BR0016385A (pt)	2003-02-18
ZA200204391B (en)	2003-11-26
KR20020060987A (ko)	2002-07-19
TR200201512T2 (tr)	2002-09-23
MXPA02005613A (es)	2002-12-13
CN1433313A (zh)	2003-07-30
EP1237553B1 (en)	2006-01-04
EA200200649A1 (ru)	2002-12-26
EA006391B1 (ru)	2005-12-29
NZ545907A (en)	2007-07-27
AU1851101A (en)	2001-06-18
CY1105014T1 (el)	2009-11-04
DE60025398D1 (de)	2006-03-30
EP1237553A2 (en)	2002-09-11
CN101406465A (zh)	2009-04-15
HRP20020527A2 (en)	2004-12-31
CO5251409A1 (es)	2003-02-28
YU41902A (sh)	2005-06-10
WO2001041701A3 (en)	2001-12-13
US20090176808A1 (en)	2009-07-09
KR100832026B1 (ko)	2008-05-23
ATE314849T1 (de)	2006-02-15
EP2036564A1 (en)	2009-03-18
SK7962002A3 (en)	2002-09-10
ES2255519T3 (es)	2006-07-01
HUP0203586A3 (en)	2005-02-28
DK1237553T3 (da)	2006-05-15
IL149994A (en)	2007-07-24
WO2001041701A2 (en)	2001-06-14

Publication	Publication Date	Title
KR100832026B1 (ko)	2008-05-23	세로토닌 재흡수 저해제와 5-ｈｔ2ｃ 길항제, 역성 효현제또는 부분 효현제의 조합
JP6245983B2 (ja)	2017-12-13	パーキンソン病におけるジスキネジアを治療するための新規ｄ３ドーパミン受容体アゴニスト
WO2007084535A2 (en)	2007-07-26	Neuronal nicotinic receptor ligands and their use
JP2026062924A (ja)	2026-04-10	神経精神障害及び疾患のための疾患修飾処置としてのデキストロメサドン
KR20050012284A (ko)	2005-01-31	세로토닌 재흡수 저해제가 사용되는 병용 치료법
KR20060032633A (ko)	2006-04-17	벤조디아제핀 수용체의 알파 3 서브유닛에 대한 선택성을갖는 화합물을 사용한 중추신경계 장애의 치료 또는 예방방법
JP2007504181A (ja)	2007-03-01	セロトニン再取り込み阻害剤およびロキサピンの併用
KR20060072127A (ko)	2006-06-27	세로토닌 재흡수 억제제 및 록사핀의 조합
KR20060124639A (ko)	2006-12-05	세로토닌 재흡수 억제제 및 히스타민 ３ 수용체안타고니스트, 역 아고니스트 또는 부분 아고니스트의 조합
KR20060066729A (ko)	2006-06-16	우울증 치료를 위한 세로토닌 재흡수 억제제 및 글리신트랜스포터 타입 1 억제제의 조합
EP1782813A1 (en)	2007-05-09	The combination of a serotonin reuptake inhibitor and a 5-HT2C antagonist, inverse agonist or partial agonist
Chadda et al.	2020	Treatment of Depression
HK1055682A (en)	2004-01-21	The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist
JP2007504180A (ja)	2007-03-01	セロトニン再取り込み阻害剤およびアモキサピンの併用
AU2009202463A1 (en)	2009-07-09	Not Given
UA81248C2 (en)	2007-12-25	Combination therapy wherein a serotonin reuptake inhibitor is used and compounds, which are a gabab receptor antagonist, inverse agonist or partial agonist